Welcome to LookChem.com Sign In|Join Free

CAS

  • or

200125-70-8

Post Buying Request

200125-70-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

200125-70-8 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 200125-70-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,0,1,2 and 5 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 200125-70:
(8*2)+(7*0)+(6*0)+(5*1)+(4*2)+(3*5)+(2*7)+(1*0)=58
58 % 10 = 8
So 200125-70-8 is a valid CAS Registry Number.

200125-70-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name (S)-2-methyl-1,2,3,4-tetrahydroquinoline

1.2 Other means of identification

Product number -
Other names (S)-2-Methyl-1,2,3,4-tetrahydro-quinoline

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:200125-70-8 SDS

200125-70-8Relevant articles and documents

Highly enantioselective hydrogenation of quinolines under solvent-free or highly concentrated conditions

Wang, Zhi-Jian,Zhou, Hai-Feng,Wang, Tian-Li,He, Yan-Mei,Fan, Qing-Hua

, p. 767 - 769 (2009)

The phosphine-free chiral cationic Ru(OTf)(TsDPEN)(η6- cymene) complex was found to be an efficient catalyst for the enantioselective hydrogenation of quinolines under more environmentally friendly solvent-free or highly concentrated conditions

Manganese-Catalyzed Asymmetric Hydrogenation of Quinolines Enabled by π–π Interaction**

Liu, Chenguang,Wang, Mingyang,Liu, Shihan,Wang, Yujie,Peng, Yong,Lan, Yu,Liu, Qiang

supporting information, p. 5108 - 5113 (2021/01/21)

The non-noble metal-catalyzed asymmetric hydrogenation of N-heteroaromatics, quinolines, is reported. A new chiral pincer manganese catalyst showed outstanding catalytic activity in the asymmetric hydrogenation of quinolines, affording high yields and enantioselectivities (up to 97 % ee). A turnover number of 3840 was reached at a low catalyst loading (S/C=4000), which is competitive with the activity of most effective noble metal catalysts for this reaction. The precise regulation of the enantioselectivity were ensured by a π–π interaction.

Enantiodivergent Synthesis of Chiral Tetrahydroquinoline Derivatives via Ir-Catalyzed Asymmetric Hydrogenation: Solvent-Dependent Enantioselective Control and Mechanistic Investigations

Han, Zhengyu,Liu, Gang,Yang, Xuanliang,Dong, Xiu-Qin,Zhang, Xumu

, p. 7281 - 7291 (2021/06/30)

Ir-catalyzed asymmetric hydrogenation of quinolines was developed, and both enantiomers of chiral tetrahydroquinoline derivatives could be easily obtained, respectively, in high yields with good enantioselectivities through the adjustment of reaction solvents (toluene/dioxane: up to 99% yield, 98% ee (R), TON = 680; EtOH: up to 99% yield, 94% ee (S), TON = 1680). It provided an efficient and simple synthetic strategy for the enantiodivergent synthesis of chiral tetrahydroquinolines, and gram-scale asymmetric hydrogenation proceeded well with low-catalyst loading in these two reaction systems. A series of deuterium-labeling experiments, control experiments, and 1H NMR and electrospray ionization-mass spectrometry experiments have been conducted, and a reasonable and possible reaction process was revealed on the basis of these useful observations.

DUAL KINASE-BROMODOMAIN INHIBITORS

-

Page/Page column 92; 124, (2021/12/12)

Provided herein are compounds of Formula (I) that are dual inhibitors of kinases and bromo-domain proteins. The disclosure also relates to pharmaceutical compositions containing such compounds, methods for using such compounds in the treatment of cancers, particularly, the treatment of multiple myeloma cancers, and to related uses.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 200125-70-8